API Gallery
The market for levothyroxine sodium is projected to grow at a CAGR of 4.5% from 2025 to 2035, driven by the increasing global prevalence of hypothyroidism, especially among women and the elderly, as well as improved thyroid screening and awareness initiatives.
The Bromhexine Hydrochloride market is witnessing a CAGR of 5.5% during the forecast period of 2025-2035. Bromhexine Hydrochloride is a vital mucolytic drug commonly employed in the pharmaceutical sector for the treatment of respiratory diseases.
The Bromhexine market is witnessing a CAGR of 6.5% during the forecast period of 2025-2035.
The Brompheniramine Maleate market is witnessing a CAGR of 3.5% during the forecast period of 2025-2035. Brompheniramine Maleate is a widely used first-generation antihistamine primarily employed for the treatment of allergic reactions, hay fever, and the common cold.
The Buclizine Hydrochloride market is witnessing a CAGR of 3.5% during the forecast period of 2025-2035.
The Budesonide market is witnessing a CAGR of 6.5% during the forecast period of 2025-2035.
The Bufalin market is witnessing a CAGR of 5.5% during the forecast period of 2025-2035.
The Bumetanide market is witnessing a CAGR of 6.5% during the forecast period of 2025-2035.
The Bupivacaine market is witnessing a CAGR of 6.5% during the forecast period of 2025-2035.
The Bromfenac Sodium market is witnessing a CAGR of 4.5% during the forecast period of 2025-2035.
The Bromocriptine Mesylate market is witnessing a CAGR of 4.5% during the forecast period of 2025-2035.
The global market for lidocaine HCl is expected to grow at a CAGR of 4.6% from 2025 to 2035, driven by increasing surgical volume, rising preference for minimally invasive and outpatient procedures, and growing demand for safe, fast-acting anesthetics.
The global market for lidocaine HCl is expected to grow at a CAGR of 4.6% from 2025 to 2035, driven by increasing surgical volume, rising preference for minimally invasive and outpatient procedures, and growing demand for safe, fast-acting anesthetics.
The global lidocaine market is projected to grow at a CAGR of around 4.4% from 2025 to 2035, driven by increasing demand for minor outpatient procedures, expanding use in dermatology and cosmetic surgery, and its inclusion in over-the-counter (OTC) topical pain relief products.
Lifitegrast is a novel, small-molecule LFA-1 antagonist used primarily for the treatment of dry eye disease (DED), a multifactorial condition characterized by ocular surface inflammation and tear film instability.
Search from 10,000 + API reports
How can we help you?
Reach out to discuss how our team can help your business achieve real results.
